Current status of xenotransplantation and prospects for clinical application

Richard N. Pierson, Anthony Dorling, David Ayares, Michael A. Rees, Jörg D. Seebach, Jay A. Fishman, Bernhard J. Hering, David K.C. Cooper

Research output: Contribution to journalReview articlepeer-review

103 Scopus citations


Xenotransplantation is one promising approach to bridge the gap between available human cells, tissues, and organs and the needs of patients with diabetes or end-stage organ failure. Based on recent progress using genetically modified source pigs, improving results with conventional and experimental immunosuppression, and expanded understanding of residual physiologic hurdles, xenotransplantation appears likely to be evaluated in clinical trials in the near future for some select applications. This review offers a comprehensive overview of known mechanisms of xenograft injury, a contemporary assessment of preclinical progress and residual barriers, and our opinions regarding here breakthroughs are likely to occur.

Original languageEnglish (US)
Pages (from-to)263-280
Number of pages18
Issue number5
StatePublished - Sep 2009


  • Antibody-mediated rejection
  • Coagulation
  • Genetic engineering, pig
  • Pancreatic islets, pig
  • Pig
  • Xenotransplantation
  • α1,3-galactosyltransferase gene-knockout


Dive into the research topics of 'Current status of xenotransplantation and prospects for clinical application'. Together they form a unique fingerprint.

Cite this